Sort   by:  
 Page size 
UnknownHydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms.
Not available
S-EPMC8327916 | biostudies-literature
UnknownRuxolitinib for the Treatment of Essential Thrombocythemia.
Not available
S-EPMC6746005 | biostudies-literature
UnknownEfficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
Not available
S-EPMC3586170 | biostudies-literature
UnknownRuxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
Not available
S-EPMC6410531 | biostudies-literature
UnknownMyeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
Not available
S-EPMC4872304 | biostudies-literature
UnknownFedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Not available
S-EPMC7317815 | biostudies-literature
UnknownIntravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
Not available
S-EPMC10600726 | biostudies-literature
UnknownPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
Not available
S-EPMC4979120 | biostudies-literature
UnknownSilk garments plus standard care compared with standard care for treating eczema in children: A randomised, controlled, observer-blind, pragmatic trial (CLOTHES Trial).
Not available
S-EPMC5388469 | biostudies-literature
UnknownPhiladelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Not available
S-EPMC5986069 | biostudies-literature
Sort   by:  
 Page size